ストックスクリーナーアプリを入手
112.71
1.54%
1.71
アフターアワーズ：
112.00
-0.71
-0.63%
前日終値:
$111.00
開ける：
$110.28
24時間の取引高:
522.95K
Relative Volume:
0.77
時価総額：
$4.71B
収益：
-
当期純損益:
-
株価収益率:
-119.90
EPS:
-0.94
ネットキャッシュフロー:
-
1週間 パフォーマンス:
-1.47%
1か月 パフォーマンス:
+2.31%
6か月 パフォーマンス:
+159.34%
1年 パフォーマンス:
+0.00%
1日の値動き範囲:
$109.84
$113.52
1週間の範囲:
$104.98
$113.91
52週間の値動き範囲:
$32.00
$131.24
Veradermics Inc Stock (MANE) Company Profile
Compare MANE vs VRTX, REGN, ARGX, RVMD, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
MANE
Veradermics Inc
|
112.71 | 4.56B | 0 | 0 | 0 | -0.94 |
VRTX
Vertex Pharmaceuticals Inc
|
505.75 | 133.25B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
803.48 | 82.16B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
851.29 | 54.80B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
203.71 | 43.99B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
347.48 | 40.62B | 5.76B | 514.49M | 1.10B | 4.4813 |
Veradermics Inc Stock (MANE) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-03-02 | 開始されました | Cantor Fitzgerald | Overweight |
| 2026-03-02 | 開始されました | Citigroup | Buy |
| 2026-03-02 | 開始されました | Jefferies | Buy |
| 2026-03-02 | 開始されました | Leerink Partners | Outperform |
Veradermics Inc (MANE) 最新ニュース
Veradermics (MANE) holder SR One sells 321,749 shares, cuts stake to 4.9% - Stock Titan
John Childs Sells 100,000 Shares of Veradermics (NYSE:MANE) Stock - MarketBeat
Planned MANE (MANE) insider common stock sale and recent IPO activity - Stock Titan
Veradermics (MANE) director-linked trusts sell 100,000 shares of common stock - Stock Titan
Veradermics (MANE) Stock Forecast and Price Target 2026 - MarketBeat
Citi Maintains Veradermics(MANE.US) With Buy Rating, Maintains Target Price $160 - Moomoo
Needham Maintains Veradermics(MANE.US) With Buy Rating, Maintains Target Price $164 - Moomoo
Veradermics, Inc SEC Filing (Aug 12, 2026) - stocktitan.net
Veradermics: Q2 Earnings Snapshot - theheraldreview.com
MANE SWOT Analysis: Financial Challenges and Competitive Landsca - GuruFocus
Veradermics Q2 Results: EPS of $(0.58) Beats Estimate - scanx.trade
Veradermics (NYSE: MANE) posts larger loss as cash surges above $800M - Stock Titan
Veradermics Announces Q2 2026 Financial Results in SEC 8-K Filing - Kalkine Media
Veradermics Reports Second Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress - BioSpace
Form 8K VERADERMICS For: 11 August By Investing.com - Investing.com Australia
Veradermics reports Q2 2026 net loss $23.5M; cash $819.9M funds operations into 2030 - TradingView
Veradermics' Q2 Net Loss Widens - marketscreener.com
Earnings Flash (MANE) Veradermics Posts Q2 Net Loss $23.5M, vs. FactSet Est of $26.8M Loss - marketscreener.com
IPO Databook: Veradermics (MANE US)Aug 2026 - Smartkarma
FMR LLC discloses 7.6% Veradermics Inc. (MANE) ownership in Schedule 13G - Stock Titan
Enterprise value to EBIT forward of Veradermics, Incorporated – NYSE:MANE - TradingView
Price to earnings forward of Veradermics, Incorporated – NYSE:MANE - TradingView
Price to sales forward of Veradermics, Incorporated – NYSE:MANE - TradingView
Enterprise value to revenue forward of Veradermics, Incorporated – NYSE:MANE - TradingView
Veradermics (MANE) Positioned to Disrupt Hair Loss Market - Yahoo Finance
Veradermics, Inc. (MANE): Six Months Later: Hair Today, Higher Tomorrow, 2026's Breakout Story - Smartkarma
Veradermics Falls 4.4% as Lock-Up Expiry Appears to Weigh on Shares - Moomoo
Certain Options of Veradermics, Incorporated are subject to a Lock-Up Agreement Ending on 3-AUG-2026. - marketscreener.com
14,570,076 Common Stock of Veradermics, Incorporated are subject to a Lock-Up Agreement Ending on 29-JUL-2026. - marketscreener.com
Veradermics, Incorporated's Lock-Up Period Set To End on August 3rd (NYSE:MANE) - MarketBeat
Veradermics, Incorporated Revenue Breakdown – NYSE:MANE - TradingView
Veradermics' Oral Hair Loss Drug for Women Shows Results In Just 2 Months - Yahoo Finance
LifeSci Capital Maintains Veradermics(MANE.US) With Buy Rating, Maintains Target Price $170 - Moomoo
symbol__ Stock Quote Price and Forecast - CNN
Veradermics shares climb 9% after encouraging female hair loss trial results (MANE) - MSN
Veradermics presents subgroup analysis of hair loss drug trial By Investing.com - Investing.com Canada
Veradermics Announces Presentations of Data from a Subgroup Analysis of Phase 2/3 Study ‘302’ in Males with Pattern Hair Loss at 2026 American Academy of Dermatology Innovation Academy - Yahoo Finance
Pattern hair-loss study analyzes men under 40 and men 40 and older - Stock Titan
Veradermics Is Maintained at Buy by Citigroup - Moomoo
MANE Maintained by Citigroup -- Price Target Raised to $160 - GuruFocus
Why Veradermics Stock Fell Today - Quiver Quantitative
Veradermics keeps ‘momentum going’ as baldness drug helps women with hair loss - BioPharma Dive
Veradermics stock jumps again on female hair loss drug win - Clinical Trials Arena
Veradermics jumps after mid-stage trial data for lead drug in female pattern hair loss - MSN
MANE Stock Draws Traders As Volatility And Cash Pile Stand Out - StocksToTrade
Why is MANE stock rising today? - MSN
LifeSci Capital Maintains Veradermics(MANE.US) With Buy Rating, Raises Target Price to $170 - Moomoo
Why Is MANE Stock Rising Today? - TradingView
Buzzy Veradermics shows its oral minoxidil can tackle female pattern hair loss, too - Fierce Pharma
Veradermics (MANE) Sees 13.9% Increase in Stock Price - GuruFocus
Veradermics Hair Loss Pill Shows Strong Phase II Signal in Women - Yahoo Finance
Veradermics Inc (MANE) 財務データ
収益
当期純利益
現金流量
EPS
0.52%
0.07%
大文字化:
|
ボリューム (24 時間):